All News

PhRMA announced 430 new medicines in development to treat chronic diseases affecting older Americans.

GSK Biologicals receives warning about cGMP compliance issues at its Quebec facility.

According to the National Bioscience Report, the US bioscience industry is on course for continued growth.

FDA approved Cubist's treatment for skin infections including MRSA.

NIH launched 3D Print Exchange, a public website promoting health and science applications of 3D printing.

Shire reports that AbbVie offer undervalued company.

Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers.

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

New services manage clinical or drug manufacturing data in the Verizon cloud or from data centers.

EDQM details the agency?s accomplishments in 2013.

Big pharma employment dropped by 3% between 2003 and 2013, according to a new jobs report published by EP Vantage.

FDA inspection found cGMP violations in the Bangalore, India API manufacturing facility.

The National Institutes of Health and the National Science Foundation set up biomedical innovation and business program.

FDA issues guidance on the use of social media in regards to prescription drugs.

Hospira announces a voluntary nationwide recall due to particulates from a glass defect.

ISPE Metrics Pilot Program is designed to demonstrate the feasibility and value of standard quality metrics.

FDA provides advice to supply-chain stakeholders on how to identify suspect drug products and how to notify the agency of those products.

Novartis facility becomes the first US site licensed by the FDA to produce cell-culture influenza vaccines.

Catalent and AAPS announce the five winners of its annual academic competition.

A new report from GlobalData states that biosimilars will overtake the market share after 2019.

The fabrication facility will supply modular construction to the US life-science market.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Draft guidance from FDA includes information essential for the completion of ANDA applications.

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

Merck acquires Idenix Pharmaceuticals for $3.85 billion.

EMA publishes revised guideline on the acceptability of names for drugs.

FDA issues a Form 483 to Wockhardt for quality issues at Morton Grove, IL facility.

Innovative polyethylene film sets new benchmark

Genia's DNA-sequencing platform will strengthen Roche's pipeline.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.